Official websites use .gov

A .gov website belongs to an official government organization in the United States.

Secure .gov websites use HTTPS

A lock ( 🔒 ) or https:// means you've safely connected to the .gov website. Share sensitive information only on official, secure websites.

Need Help

(1/2) Catheter Ablation Versus Antiarrhythmic and Heart Failure Drug Therapy in Preserved Ejection Fraction Heart Failure (CABANA-HF)

Award Number: UG3HL182948
ORGANIZATION: NATIONAL HEART, LUNG, & BLOOD INSTITUTE
OPDIV: NIH
AWARD CLASS: COOPERATIVE AGREEMENT
AWARD ACTIVITY TYPE: SCIENTIFIC/HEALTH RESEARCH (INCLUDES SURVEYS)
PERIOD OF PERFORMANCE START DATE: 07/10/2026
PERIOD OF PERFORMANCE END DATE: 06/30/2027

Group Awards By:

View Award Description

(1/2) Catheter Ablation Versus Antiarrhythmic and Heart Failure Drug Therapy in Preserved Ejection Fraction Heart Failure (CABANA-HF) - Project Summary Based on emerging data regarding the increase in morbidity and mortality among patients with heart failure with preserved ejection fraction (HFpEF) and atrial fibrillation (AF), there is a consensus for the need of a large, multi- center clinical trial to determine whether AF ablation in addition to guideline-directed medical therapy (GDMT) for HF provides additive benefit compared to GDMT alone. An ideal trial would enroll a sufficiently broad spectrum of patients to allow far-reaching applicability to the dramatically increasing numbers of patients with HFpEF and AF and yet would collect data to determine whether treatment efficacy varies across patient subtypes and underlying pathophysiology (e.g., extent of left atrial [LA] myopathy). Here we propose CABANA-HF, a 1552- patient, 2-arm randomized clinical trial conducted over 5 years (3 years of recruitment and 2 years of follow-up). The primary aim of CABANA-HF is to definitively determine whether standard percutaneous LA catheter ablation plus GDMT is superior to GDMT alone in HFpEF with AF. The primary endpoint will be the composite of cardiovascular (CV) mortality or worsening HF, defined as an unplanned hospitalization for HF or an urgent visit for HF. A blinded (to treatment assignment) independent Clinical Events Committee will review and classify all primary and major clinical secondary events. Major secondary endpoints of the trial will include all-cause mortality, all-cause mortality or worsening HF events, primary outcome components, time to recurrent AF, AF burden, quality of life, and incremental cost effectiveness. We will enroll patients with paroxysmal, persistent, or long-standing persistent AF plus HFpEF (ejection fraction ≥50%); NYHA functional class II or III symptoms; and ≥1 additional risk factor for worsening HF or death. Patients who are judged likely to require early AF ablation for adequate symptom control by the site investigative team will be excluded due to high likelihood of early crossover. Other exclusion criteria will focus on major comorbid conditions likely to create competing risks (e.g., restrictive cardiomyopathies, sustained ventricular tachycardia, severe valve disease, inability to take oral anticoagulants, as well as evidence of clinically refractory HF or unstable AF despite optimal GDMT). The concern of increasing morbidity and mortality in HFpEF patients with AF, along with limitations in results of past studies and preliminary data, provides a sufficient incentive to undertake this trial with an anticipated high likelihood of predicting a positive and informative outcome of the CABANA-HF trial.


Issue Date FY	Funding FY	Legal Entity Name	Legal Entity Address	Legal Entity City	Legal Entity State	Legal Entity Zip Code	Legal Entity COUNTY	Legal Entity COUNTRY	Assistance Listing	Award Code	Budget Year	Action Date	Action Type	Action Amount

Issue Date FY: 2026 ( Subtotal = $1,293,639 )
2026	2026	IHC HEALTH SERVICES INC	36 S STATE ST	SALT LAKE CITY	UT	84111	SALT LAKE	USA	Cardiovascular Diseases Research	000	1	7/9/2026	NEW	$1,293,639
														Subtotal = $1,293,639

Grand Total All Awards = $1,293,639

Top

All Categories

About

Search

Reports

Data Submission

Award Information

(1/2) Catheter Ablation Versus Antiarrhythmic and Heart Failure Drug Therapy in Preserved Ejection Fraction Heart Failure (CABANA-HF)

Award Number: UG3HL182948

ORGANIZATION: NATIONAL HEART, LUNG, & BLOOD INSTITUTE

OPDIV: NIH

AWARD CLASS: COOPERATIVE AGREEMENT

AWARD ACTIVITY TYPE: SCIENTIFIC/HEALTH RESEARCH (INCLUDES SURVEYS)

PERIOD OF PERFORMANCE START DATE: 07/10/2026

PERIOD OF PERFORMANCE END DATE: 06/30/2027

Federal Websites

Department of Health & Human Services

HHS Operating Divisions

HHS Staff Divisions

Download A Document Viewer